Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts (2022)
- Authors:
- USP affiliated authors: SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; ROSSI, GIORDANO NOVAK - FMRP ; ROCHA, JULIANA MENDES - FMRP
- Unidade: FMRP
- DOI: 10.3390/psychoactives1010003
- Subjects: ALUCINOGÊNICOS; SAÚDE MENTAL; COVID-19
- Keywords: Hallucinogens; Psychedelic drugs; Coping; Mental health
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Psychoactives
- ISSN: 2813-1851
- Volume/Número/Paginação/Ano: v. 1, n. 1, p. 16-30, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
ONA, Genís et al. Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts. Psychoactives, v. 1, n. 1, p. 16-30, 2022Tradução . . Disponível em: https://doi.org/10.3390/psychoactives1010003. Acesso em: 29 maio 2024. -
APA
Ona, G., Révész, D., Kohek, M., Rossi, G. N., Rocha, J. M., Santos, R. G. dos, et al. (2022). Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts. Psychoactives, 1( 1), 16-30. doi:10.3390/psychoactives1010003 -
NLM
Ona G, Révész D, Kohek M, Rossi GN, Rocha JM, Santos RG dos, Hallak JEC, Alcázar-Córcoles MÁ, Bouso JC. Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts [Internet]. Psychoactives. 2022 ; 1( 1): 16-30.[citado 2024 maio 29 ] Available from: https://doi.org/10.3390/psychoactives1010003 -
Vancouver
Ona G, Révész D, Kohek M, Rossi GN, Rocha JM, Santos RG dos, Hallak JEC, Alcázar-Córcoles MÁ, Bouso JC. Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts [Internet]. Psychoactives. 2022 ; 1( 1): 16-30.[citado 2024 maio 29 ] Available from: https://doi.org/10.3390/psychoactives1010003 - Adverse effects after Ayahuasca administration in the clinical setting [Carta]
- The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020)
- Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
- Can hallucinogens alter personality functioning?: results of a clinical trial involving the Pfister’s Colors Pyramids test
- The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
- Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
- Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies
- Molecular pathways of the therapeutic effects of Ayahuasca, a botanical psychedelic and potential rapid-acting antidepressant
- Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms
- Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
Informações sobre o DOI: 10.3390/psychoactives1010003 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
